Facebook
Twitter
LinkedIn
Forward
Do Not Drink, Do Not Drive: Alcohol Use Disorder in the Elderly
Instructions
Click the REGISTER button to take the posttest.
Click here to return to the PCC CME article
Overview
When older patients present with cognitive decline, it is important to rule out any organic, mood-related, or substance-induced etiology, such as alcohol use disorder.
Read the whole article at psychiatrist.com here:
Do Not Drink, Do Not Drive: Alcohol Use Disorder in the Elderly
© Copyright 2021 Physicians Postgraduate Press, Inc.
Target Audience
Primary care clinicians
Learning Objectives
Screen elderly patients for alcohol use disorder
CME Background
Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.
CME Objective
After studying this article, you should be able to:
- Screen elderly patients for alcohol use disorder
Statement of Need and Purpose
Both driving and alcohol use disorder (AUD) can be problematic for older patients, especially if they develop dementia. Many clinicians need education on the value of regularly assessing older patients for cognitive impairment/dementia and AUD using standardized tools. Clinicians must also communicate with patients and their caregivers about driving ability and helping the patient determine when it is time to cease driving.
Release, Expiration, and Review Dates
This educational activity was published in October 2021 and is eligible for AMA PRA Category 1 Credit™ through October 31, 2023. The latest review of this material was October 2021.
Case Conference
The Banner Alzheimer’s Institute Case Conference is a weekly event in which physicians and staff discuss challenging and/or teaching cases of patients seen at the Institute’s Stead Family Memory Clinic. These conferences are attended by a multidisciplinary group that includes Banner Alzheimer’s Institute dementia specialists, community physicians (internal medicine, family medicine, and radiology), physician assistants, social workers, nurses, medical students, residents, and fellows. The Banner Alzheimer’s Institute, located in Phoenix, Arizona, has an unusually ambitious mission: to end Alzheimer’s disease without losing a generation, set a new standard of care for patients and families, and forge a model of collaboration in biomedical research. The Institute provides high-level care and treatment for patients affected by Alzheimer’s disease, dementia, and related disorders. In addition, the Institute offers extensive support services for families and many unique and rewarding research opportunities.
Disclosure of Off-Label Usage
The authors have determined that, to the best of their knowledge, gabapentin and topiramate are not approved by the US Food and Drug Administration for the treatment of alcohol use disorder.
Funding/Support
None.
Disclaimer
The opinions expressed are those of the authors, not of Banner Health or Physicians Postgraduate Press, Inc.
Faculty Affiliation
Ganesh Gopalakrishna, MD
Banner Alzheimer’s Institute, and Department of Psychiatry, University of Arizona College of Medicine, Phoenix, Arizona
Nisha Patel, DO
Department of Psychiatry, University of Arizona College of Medicine, Phoenix, Arizona
*Corresponding authors: Ganesh Gopalakrishna, MD, Stead Memory Clinic, Banner Alzheimer’s Institute, 901 E Willetta St, Phoenix AZ 85006 ([email protected]).
Financial Disclosure
All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Larry Culpepper, MD, MPH, Editor in Chief of The Primary Care Companion for CNS Disorders, has been a consultant for AbbVie, Acadia, Allergan, Eisai, Merck, and Takeda; has been a stock shareholder of M-3 Information; and has received royalties from UpToDate and Oxford University Press. No member of the CME Institute staff reported any relevant personal financial relationships.
Drs Gopalakrishna and Patel have no personal affiliations or financial relationships with any commercial interest to disclose relative to this article.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation